Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Beluga Health vs Direct Meds

Beluga Health
Graded #431

Lower grade

vs+26.799999999999997
Direct Meds
Graded #19

Higher grade

The verdict

Direct Meds takes it — 82.6/100 to 55.8/100.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDirect Meds +40
45
85
Dose & formulationDirect Meds +48
40
88
Clinical oversightDirect Meds +4
76
80
Labs & monitoringDirect Meds +16
62
78
FulfillmentDirect Meds +16
64
80
Contract termsDirect Meds +25
55
80
Beluga Health · left barDirect Meds · right bar

The numbers

MetricBeluga HealthDirect Meds
WeighScore55.8/10082.6/100
GradeCB−
Scorecard rank#431#19
SemaglutideNot disclosed$179/mo
TirzepatideNot disclosed$224/mo
CoverageCoverage not publishedNot publicly listed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Beluga Health

Graded #431 · C

Strengths

  • Supports GLP-1 care with compounded semaglutide and tirzepatide
  • Board-certified providers and a 50-state medical infrastructure
  • LegitScript certified with SOC 2 and ISO 27001 security
  • Pharmacies follow FDA/USP standards with third-party batch testing
  • Powers many DTC brands as a turnkey telehealth backbone

Where it loses points

  • White-label B2B group, not a direct consumer-facing service
  • Offers compounded, not FDA-approved branded, GLP-1s
  • No public consumer pricing for the GLP-1 offering
  • Cited among nationwide groups tied to FDA telehealth GLP-1 scrutiny
  • Care quality varies by the consumer brand using the platform
Direct Meds

Graded #19 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard